



LFw

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/603,000
	Filing Date	06/23/2003
	First Named Inventor	David S.F. Young et al
	Art Unit	1643
	Examiner Name	David J. Blanchard
Total Number of Pages in This Submission	Attorney Docket Number	2056.020

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Corroboration for Deposited Materials;
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Patent Assignment - Abstract of Title (2)
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	McHale & Slavin, P.A.	
Signature	<i>Ferris H. Lander</i>	
Printed name	Ferris H. Lander	
Date	7/25/2006	Reg. No. 43,377

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature	<i>Cathy Nicholson</i>	
Typed or printed name	Cathy Nicholson	Date 7/25/06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR : David S. F. Young et al
INVENTION : CANCEROUS DISEASE MODIFYING ANTIBODIES
SERIAL NUMBER : 10/603,000
FILING DATE : June 23, 2003
EXAMINER : David J. Blanchard
GROUP ART UNIT : 1643
ATTORNEY DOCKET NO. : 2056.020

CERTIFICATE UNDER 37 CFR §1.8(a)
I hereby certify that this correspondence is being deposited with
the U.S. Postal Service as First Class mail in an envelope
addressed to Commissioner for Patents, P.O. Box 1450,
Alexandria, VA 22313-1450 on 7/25/06

[Signature]

CORROBORATION FOR DEPOSITED MATERIALS

Mail Stop Non-Fee Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Ferris H. Lander, a person in a position to corroborate that the hybridoma cell line which was deposited in accordance with the Budapest Treaty, with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA 20110-2209 on September 4, 2002 under Accession No. PTA-4621 designated H460-16-2, do hereby state that this deposited hybridoma cell line is the same hybridoma cell line disclosed in the above-referenced patent application.

Respectfully submitted,

Date 7/25/2006

By Ferris H. Lander
Ferris H. Lander
Registration No. 43,377
McHale & Slavin, P.A.
2855 PGA Boulevard
Palm Beach Gardens, FL 33410
Telephone: (561) 625-6575
Facsimile: (561) 625-6572

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : David S. F. Young et al

INVENTION : **CANCEROUS DISEASE MODIFYING ANTIBODIES**


SERIAL NUMBER : 10/603,000

FILING DATE : June 23, 2003

EXAMINER : David J. Blanchard

GROUP ART UNIT : 1643

OUR FILE NO. : 2056.020



CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on 7/25/06

TO:
Mail Stop: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION OF April 25, 2006

Sir:

In response to the Office Action dated April 25, 2006 having a shortened statutory period for response set to expire July 25, 2006, kindly amend the above-entitled application as follows, no new matter is added:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 12 of this paper.

Remarks/Arguments begin on page 17 of this paper.